MedPath

Appili Therapeutics Receives Positive FDA Feedback on ATI-1801 Development for NDA Submission

• Appili Therapeutics announced that the FDA has provided positive feedback on its development strategy for ATI-1801, a topical antiparasitic product. • The FDA's feedback aligns with the requirements for a New Drug Application (NDA) submission, marking a significant milestone for the drug's development. • Aditxt's planned acquisition of Appili Therapeutics could be bolstered by the progress of ATI-1801 towards potential market approval.

Aditxt, Inc. has announced a significant milestone for its target acquisition, Appili Therapeutics Inc., with the U.S. Food and Drug Administration (FDA) providing positive feedback on the development strategy for ATI-1801, Appili's topical antiparasitic product. This alignment with the FDA is a crucial step toward the New Drug Application (NDA) submission.

Development of ATI-1801

ATI-1801 is being developed as a topical antiparasitic treatment. Appili Therapeutics is strategically focused on identifying and developing novel therapies for urgent infections with unmet needs. The company's pipeline includes an FDA-approved metronidazole suspension, a vaccine candidate against biological weapons, and the ATI-1801 topical antiparasitic.

Strategic Implications for Aditxt

Aditxt's interest in Appili Therapeutics is part of a broader strategy to expand its portfolio of health innovations. Aditxt is also pursuing a merger agreement with Evofem Biosciences, Inc. The closing of the acquisition of Appili is subject to several conditions, including approval by target shareholders and Aditxt raising sufficient capital.

About Appili Therapeutics Inc.

Appili Therapeutics is dedicated to solving life-threatening infections. The company focuses on systematically identifying urgent infections with unmet needs and strategically developing a pipeline of novel therapies to prevent deaths and improve lives.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Grants Priority Review to Vatiquinone for Friedreich's Ataxia Treatment

The FDA has accepted PTC Therapeutics' NDA for vatiquinone, a potential treatment for Friedreich's ataxia (FA), granting it priority review.
Vatiquinone aims to address the unmet need for FA patients, particularly children, by targeting energetic and oxidative stress pathways.

FDA Accepts Crinetics' Paltusotine NDA for Acromegaly Treatment

The FDA has accepted Crinetics Pharmaceuticals' NDA for paltusotine for acromegaly, setting a target action date of September 25, 2025.
If approved, paltusotine will be the first once-daily, oral somatostatin receptor type 2 agonist for acromegaly, offering an alternative to injectables.

FDA Approves PTC Therapeutics' Kebilidi, a Gene Therapy for AADC Deficiency

The FDA has granted accelerated approval to Kebilidi (eladocagene exuparvovec-tneq), a gene therapy developed by PTC Therapeutics for treating AADC deficiency.
Kebilidi is the first gene therapy approved in the US that is directly administered to the brain, offering a novel approach to treating this rare genetic disorder.

Acepodia's ACE1831 Receives FDA IND Clearance for IgG4-Related Disease Trial

Acepodia's ACE1831, an allogeneic gamma delta T cell therapy, has received FDA IND clearance for investigation in IgG4-related disease, marking Acepodia's entry into autoimmune disease treatment.
ACE1831 targets CD20-expressing cells and is designed as an off-the-shelf therapy, potentially reducing side effects associated with autologous CAR-T cell therapies.

Acepodia's ACE1831 Receives FDA IND Clearance for IgG4-Related Disease

Acepodia's ACE1831, an allogeneic gamma delta T cell therapy, has received FDA IND clearance for IgG4-related disease, marking Acepodia's entry into autoimmune disease treatment.
ACE1831 targets CD20-expressing cells and is designed as an off-the-shelf therapy, potentially reducing side effects associated with autologous CAR-T cell therapies.

FDA Approves PTC Therapeutics' KEBILIDI, First Gene Therapy Delivered Directly to the Brain for AADC Deficiency

The FDA has granted accelerated approval to PTC Therapeutics' KEBILIDI, a gene therapy for AADC deficiency, marking the first such therapy delivered directly to the brain.
KEBILIDI works by using an adeno-associated virus to deliver a functional DOPA decarboxylase gene, restoring dopamine production in patients with AADC deficiency.

Appili Therapeutics Advances Pipeline with FDA-Approved Drug Launch and Vaccine Progress

Appili Therapeutics reported a net loss of $0.8 million in Q2 FY2025, an improvement from the previous year, and anticipates closing a take-private transaction with Aditxt in December 2024.
ATI-1701, Appili's biodefense vaccine, demonstrated full protection against tularemia for one year in animal models, supported by significant funding from the U.S. Air Force Academy.

Appili Therapeutics Gains FDA Alignment on ATI-1801 Development for Leishmaniasis

Appili Therapeutics has received positive feedback from the FDA regarding its development strategy for ATI-1801, a topical antiparasitic product.
ATI-1801 is being developed for the treatment of leishmaniasis, a disfiguring parasitic disease with significant unmet medical needs.

Appili Therapeutics Gains FDA Alignment on ATI-1801 for Cutaneous Leishmaniasis

Appili Therapeutics announced FDA agreement on the development strategy for ATI-1801, a topical paromomycin formulation, streamlining its path to NDA submission.
The FDA's feedback allows Appili to leverage existing clinical data, including Phase 3 results, reducing the need for additional clinical trials.

Adicet Bio's ADI-001 Receives FDA Clearance for Expanded Autoimmune Trial

Adicet Bio's IND amendment for ADI-001 has been cleared by the FDA to include idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS) in its Phase 1 autoimmune trial.
Patient enrollment for the IIM and SPS cohort is expected to begin in the first quarter of 2025, expanding the trial to six autoimmune indications.

Reference News

[1]
Aditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on ... - Stock Titan
stocktitan.net · Oct 31, 2024

Aditxt (NASDAQ: ADTX) announces FDA's positive feedback on Appili Therapeutics' (TSX: APLI; OTCPink: APLIF) ATI-1801 dev...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy